Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Aloxi Authorized Generic Now Available Ahead of Gx Contenders
Okayama Taiho Pharmaceutical said on September 7 that it has launched an authorized generic (AG) version of the antiemetic agent Aloxi (palonosetron), almost three months after its reimbursement listing in June. In Japan, Aloxi original products are being marketed by…
To read the full story
Related Article
- Zacras AG Now Available, Aloxi AG Expected for September Launch
June 18, 2021
- 9 Drugs Face Generic Entries, AGx Debuts for 2 Brands: June Listing
June 17, 2021
- 17 Firms Get Approval for Cymbalta Generics, June Listing Eyed
February 16, 2021
BUSINESS
- Takeda Files Entyvio IV for Pediatric Use, New Adult Dosing in Japan
July 29, 2026
- MSD Urges Swift Rollout of Routine HPV Vaccination for Males in Japan
July 29, 2026
- Drug Makers, Wholesalers Rush to Gauge Kumamoto Quake Impact
July 29, 2026
- Pfizer Brings Eisai into Nurtec Promotion in Japan
July 28, 2026
- Celltrion, Nippon Kayaku Broaden Alliance in Biopharma Biz
July 28, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…